Actively Recruiting

Age: 18Years +
All Genders
NCT06849180

Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data

Led by Zhongda Hospital · Updated on 2025-02-27

198

Participants Needed

1

Research Sites

60 weeks

Total Duration

On this page

Sponsors

Z

Zhongda Hospital

Lead Sponsor

E

Eastern Hepatobiliary Surgery Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying patients with CHC subtypes based on the combination of artificial intelligence and multi-omics, and exploring the optimal treatment strategies for patients with different subtypes, helping clinicians to screen the most beneficial groups of various treatment schemes, and providing new ideas for safe treatment of high-risk patients.

CONDITIONS

Official Title

Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older with CHC confirmed by histology or cytology
  • Unresectable or metastatic CHC with prior local or systemic therapy and at least one measurable lesion
  • Expected survival time of 3 months or longer
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Child-Pugh liver function classification A or B
Not Eligible

You will not qualify if you...

  • Pregnant or lactating women, and men or women of childbearing age unwilling or unable to use effective contraception
  • History of other cancers within the past five years unless fully treated and disease-free for five years with low recurrence risk
  • Fully treated carcinoma in situ with no evidence of disease
  • History of gastrointestinal bleeding or bleeding tendency within six months that prevents study participation
  • Major organ or bone marrow transplant within two years before study start, or active autoimmune disease needing systemic therapy
  • Other conditions or incomplete data that make participation unsuitable as determined by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhongda Hospital

Nanjing, Jiangsu, China

Actively Recruiting

Loading map...

Research Team

G

Gao-Jun Teng, M.D

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data | DecenTrialz